New Novartis: Holding subsidiary SYS6023 antibody-drug conjugate obtains notification of approval for drug clinical trials.

New Novartis announcement, the holding subsidiary Stone Pharmaceuticals Group's Jushi Biopharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for SYS6023, and will soon begin clinical trials. SYS6023 is a HER3-targeted antibody-drug conjugate, which uses the company's independently developed topoisomerase I inhibitor as the payload. It can bind to specific receptors on the surface of the tumor, enter the cell through endocytosis, release toxins, and achieve the effect of killing tumor cells.